NOW FDA APPROVED

Learn More

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250165 07/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates

Aug 10, 2020

Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting

Jul 10, 2020

Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer

Jul 9, 2020

Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies

Jul 8, 2020

Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting

Jun 18, 2020

Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors

Jun 17, 2020

Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

May 28, 2020

Abeona Therapeutics Reports First Quarter Financial Results and Business Updates

May 6, 2020

Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Apr 21, 2020

Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors

Apr 21, 2020
RSS
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...32

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use